News & Events

News

Go to Archive


January 24, 2017

scPharmaceuticals Announces Start of SUBQ-HF NHLBI Study with Its Subcutaneous Furosemide Product

FOR IMMEDIATE RELEASE: LEXINGTON, MA., —scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery, announced today the start of the first phase of a study conducted by the Heart Failure Clinical Research Network (HFN).

January 4, 2017

scPharmaceuticals Announces Closing of $45.6 Million in Series B Financing

FOR IMMEDIATE RELEASE: LEXINGTON, MA. — scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round.

Events

Meet Us at an Event